Adaptyv Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Adaptyv Bio is a Zurich-based provider of automated wet-lab services specifically tailored for the AI-driven protein design sector. Founded in 2021, the company has established a 'cloud lab' that allows clients to upload protein designs digitally and receive comprehensive experimental data packages within three weeks. Its platform is designed to generate the clean, high-quality data necessary to train and refine generative AI models for protein engineering, serving as a critical infrastructure component for biotech companies pursuing novel therapeutics, enzymes, and diagnostics. By automating the experimental loop, Adaptyv accelerates the design-build-test-learn cycle for its customers.

Synthetic BiologyAI / Machine Learning

Technology Platform

A fully automated, cloud-connected laboratory platform for high-throughput protein synthesis, expression, and functional characterization (e.g., binding affinity, activity). It includes a digital portal for experiment management and an API for integration with AI/ML workflows, turning raw experimental data into clean, labeled datasets for model training.

Opportunities

The rapid adoption of generative AI for protein design creates a massive and growing demand for reliable, high-speed experimental validation.

Adaptyv's specialized, automated platform is positioned to capture this market as the preferred provider for AI-driven biotechs and pharma.

Expanding its assay menu and building a proprietary protein performance database could create significant network effects and data moats.

Risk Factors

Major risks include technological failure of the automated platform, competition from large CROs developing similar services or AI biotechs building internal capacity, and a potential slowdown in investment for AI protein design.

The capital-intensive model also creates financial risk if the company cannot achieve scale before funding runs out.

Competitive Landscape

Adaptyv competes with traditional contract research organizations (CROs) that offer protein expression and characterization services but typically lack specialization and speed for AI-driven projects. It also competes with internal R&D labs at large biopharma companies and well-funded AI biotechs (e.g., Recursion, Insitro) that may build their own automation. Its key advantage is focus, speed, and data integration tailored for the AI protein design workflow.

More companies in Proteomics & Protein Engineering →More companies in Switzerland →